Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Depreciation (2020 - 2025)

Historic Accumulated Depreciation for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $6.5 million.

  • Janux Therapeutics' Accumulated Depreciation rose 4627.5% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 4627.5%. This contributed to the annual value of $5.0 million for FY2024, which is 6993.82% up from last year.
  • Per Janux Therapeutics' latest filing, its Accumulated Depreciation stood at $6.5 million for Q3 2025, which was up 4627.5% from $6.0 million recorded in Q2 2025.
  • Janux Therapeutics' Accumulated Depreciation's 5-year high stood at $6.5 million during Q3 2025, with a 5-year trough of $39000.0 in Q2 2021.
  • Over the past 5 years, Janux Therapeutics' median Accumulated Depreciation value was $2.1 million (recorded in 2023), while the average stood at $2.5 million.
  • Per our database at Business Quant, Janux Therapeutics' Accumulated Depreciation skyrocketed by 75909.09% in 2022 and then surged by 4627.5% in 2025.
  • Quarter analysis of 5 years shows Janux Therapeutics' Accumulated Depreciation stood at $131000.0 in 2021, then soared by 641.98% to $972000.0 in 2022, then soared by 199.79% to $2.9 million in 2023, then skyrocketed by 69.94% to $5.0 million in 2024, then skyrocketed by 31.24% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $6.0 million for Q2 2025, and $5.5 million during Q1 2025.